Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Libella Gene Therapy (AAV-hTERT) for Aging
NCT04133649Phase 1Unknown
- Sponsor
- Libella Gene Therapeutics
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AAV-hTERT in aging, sponsored by Libella Gene Therapeutics. Primary endpoint: Incidence of Adverse Events at 12 months. Status: unknown.
02
Drugs
AAV-hTERT
03
Conditions
aging
Beyond the preview
Go deeper on NCT04133649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04133649.